An exciting development pipeline in pharma.
- Androgenetic Alopecia: (Clascoterone solution) is a novel androgen receptor inhibitor that targets androgen receptors in the scalp and is currently being studied for the treatment of androgenetic alopecia (AGA).
- Distal Ulcerative Colitis: (Rifamycin 1% enema) is an innovative product which combines an in situ gelling solution of Rifamycin and a newly designed delivery device, which is currently being studied for the treatment of distal Ulcerative Colitis and Proctitis.
- Bile Acid Diarrhea: (Colesevelam) formulated with Cosmo’s proprietary technology has the potential to overcome the current concerns for bile acid sequestrants for the treatment of bile acid diarrhea (BAD).
- Solid Tumors: (Cortexolone 17α-valerate-21-propionate) is an oral androgen receptor (AR) antagonist against solid tumors. It has the potential for first- and second-line therapy in pancreatic and colon cancers. Regulatory Toxicology shows oral dosing is safe and well-tolerated.
- AI Augmented Endoscopy: The number of endoscopy procedures is vast and market opportunity is significant worldwide. Cosmo’s AI technology, GI Genius™intelligent endoscopy system aims to revolutionize real-time endoscopy procedures, enhancing accuracy and outcomes, and ultimately improving patient care. For more information visit www.cosmoimd.com
By focusing on all these specific conditions and markets, Cosmo is positioning for growth and committing to addressing significant health challenges. Each of these areas represents a unique opportunity to make a meaningful impact on patients’ lives.